HIV Vaccines

Recombinant gp160 Stimulates Immune Responses in Adults With Advanced Infection

Published in Vaccine Weekly, November 1st, 2000

A recombinant HIV-1 gp160 vaccine was well tolerated and stimulated immune responses in adults with advanced HIV infection, health officials in Massachusetts reported.

In a study of the "immunogenicity of a recombinant HIV-1 envelope vaccine (rgp160) in late HIV infection," A. Demaria and colleagues, Bureau of Communicable Disease Control, Massachusetts, enrolled 142 HIV infected patients who had CD4⁺ T lymphocyte counts of <400/mm³, "in a dose-comparison, open-label trial with stratification by CD4⁺ cell count, randomization to a primary series at two dose levels, and a sub-group receiving interferon-gamma (IFN-gamma) as an...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-11-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry